science and publications

the science behind Kode Technology

Kode Technology has been described in peer-reviewed journals since 2007. Stephen Henry's DSc thesis and the Technical Manual bring the evidence together.

Kode Technology references: the manual and the thesis

Cover of the Kode Technology Illustrated Technical Manual, first edition, 2023

Kode Technology Illustrated Technical Manual

Kode Biotech, first edition 2023. All known Kode Technology data in one illustrated reference.

University of AucklandNational Library of NZ
Cover of Stephen Henry's Doctor of Science thesis, Kode Technology, The University of Auckland, 2025

Kode Technology: DSc thesis

Stephen Henry, University of Auckland, 2025. The full history and science of Kode Technology.

University of AucklandNational Library of NZ

Kode Technology: peer-reviewed publications

81 journal papers on FSL constructs, kodecytes and Kode Immunoeducers since 2007, 20 papers of related research, and 69 conference abstracts and proceedings since 2003. Newest first. Further technical material, including MSDS and technical bulletins, is on kodecyte.org.

Kode Technology bibliography

8 November 2026. Every journal paper and conference paper in one list, kept as two sections.

download PDF

Kode Technology subject index

8 November 2026. Find journal papers by material, technique, target, application or disease.

download PDF

Request a paper

Can't access a Kode Biotech–authored paper? Write to us and we'll send you a copy.

email [email protected]

Kode Technology journal papers (81)

  1. Structural basis for protocadherin-1 recognition by New World hantavirusesBattini L, Slough MM, Kaur R, Guo L, Florez C, Serris A, Meola A, Lasso G, Tischler ND, Alvarez R, Lambe UP, Khera L, Wang J, Scott RS, Garrido JL, Barria MI, Josleyn NM, Rey FA, Herbert AS, McLellan JS, Jangra RK, Chandran K, Guardado-Calvo P. 2026. Nature. DOI: 10.1038/s41586-026-11184-1
  2. Expanded protocadherin-1 usage reveals a broader hantavirus entry landscapeWord C, Guerra-Pilaquinga N, Kasikci E, Khera L, Kaur R, Lambe UP, Ortega A, Dieterle ME, Chandran K, Jangra RK. 2026. Journal of Virology 100(10):e00994-26. DOI: 10.1128/jvi.00994-26
  3. Immune antibodies recognizing the stem region of SARS-CoV-2 spike protein: Molecular modeling and in vitro study of synthetic peptides presentation to the antibodiesAliper ET, Ryzhov IM, Obukhova PS, Tuzikov AB, Galanina OE, Ziganshina MM, Sukhikh GT, Krylov NA, Henry SM, Efremov RG, Bovin NV. 2026. Biochimica et Biophysica Acta (BBA) - Biomembranes 1868(1):184472. DOI: 10.1016/j.bbamem.2025.184472
  4. Raft Selectivity of a Cholesterol Probe Capable of Forming an H-Bond with PhospholipidsRyzhov I, Rapoport E, Obukhova P, Tuzikov A, Sokolova M, Anisimova D, Galanina O, Khaidukov S, Henry S, Bovin N. 2026. Molecules 31(13):2297. DOI: 10.3390/molecules31132297
  5. Polysaccharide epitopes recognized by human α-L-Rha antibodiesShilova NV, Obukhova PS, Knirel YA, Golovchenko VV, Patova OA, Tsygankova SV, Mikshina PV, Henry S, Bovin NV. 2026. Carbohydrate Research 559:109717. DOI: 10.1016/j.carres.2025.109717
  6. Synthesis of Lipid-Conjugated Heparan Sulfate Mimetics and Their Effect on Complement InhibitionRyzhov IM, Tuzikov AB, Popova IS, Li Y, Salimi-Afjani N, Spijkers-Shaw S, Rendle PM, Rieben R, Bovin NV, Zubkova OV. 2026. ChemBioChem 27(1). DOI: 10.1002/cbic.202500262
  7. Revealing and quantifying polyclonal anti-A,B specificity in ABO histo-blood groupsHenry S, Perry H, Obukhova P, Tyrtysh T, Ryzhov I, Bovin N, Datta SS. 2026. Transfusion 66(5):965–975. DOI: 10.1111/trf.70175
  8. Using SARS-CoV-2 red cell kodecytes to assess vaccine-induced immune response to the conserved 1147-58 region of the spike protein in Indian blood donors: exploring the potential role of blood transfusion services in population surveillanceDatta SS, Hazra A, Basheela NH, Gupta K, Mondal PK, Aliper E, Bovin NV, Henry SM. 2025. Transfusion Clinique et Biologique 32(3):286-291. DOI: 10.1016/j.tracli.2025.05.001
  9. Hantavirus Gn H Nanoparticle Immunogen Elicits a Cross-Neutralizing Antibody Response in MiceRamos KE, Mariano MC, Mittler E, Pardo R, Zylberman V, Guardado-Calvo P, Chandran K, Lai JR. 2025. ACS Infectious Diseases 11(11):3061–3070. DOI: 10.1021/acsinfecdis.5c00415
  10. Antigen Presentation in an Artificial and Cell Membrane: Blood Group A Glycan RecognitionRyzhov I, Tuzikov A, Obukhova P, Sablina M, Popova I, Anisimova D, Galanina O, Shilova N, Khaidukov S, Chizhov A, Henry S, Bovin N. 2025. ChemBioChem 26(1):e202400843. DOI: 10.1002/cbic.202400843
  11. A novel syphilis Treponema pallidum lipoprotein peptide antigen diagnostic assay using red cell kodecytes in routine blood centre column agglutination testing platformsDatta SS, Nagappan R, Biswas D, Basu D, Gupta K, Mondal PK, Tuzikov A, Bovin NV, Henry SM. 2024. Vox Sanguinis 119(8):821-826. DOI: 10.1111/vox.13628
  12. Nanoparticle-based itaconate treatment recapitulates low-cholesterol/low-fat diet-induced atherosclerotic plaque resolutionHong NE, Chaplin A, Di L, Ravodina A, Bevan GH, Gao H, Asase C, Gangwar RS, Cameron MJ, Mignery M, Cherepanova O, Finn AV, Nayak L, Pieper AA, Maiseyeu A. 2024. Cell Reports 43(11):114911. DOI: 10.1016/j.celrep.2024.114911
  13. Chemical Resolution of an Epitope Recognized by Blood Group Antibodies Capable of Binding Both A and B Red Blood CellsObukhova P, Tyrtysh T, Tsygankova S, Paramonov A, Gordeeva E, Shilova N, Lipatnikov A, Sokolova M, Henry S, Salimov E, Bovin N, Ryzhov I. 2024. ChemBioChem 25(17):e202400430. DOI: 10.1002/cbic.202400430
  14. Some Human Anti-Glycan Antibodies Lack the Ability to Activate the Complement SystemShilova N, Nokel A, Lipatnikov A, Khasbiullina N, Knirel Y, Baidakova L, Tuzikov A, Khaidukov S, Obukhova P, Henry S, Shoibonov B, Salimov E, Rieben R, Bovin N. 2024. Antibodies 13(4):105. DOI: 10.3390/antib13040105
  15. Surface Glycans of Microvesicles Derived from Endothelial Cells, as Probed Using Plant LectinsSlivka EV, Shilova NV, Obraztsova EA, Kapustkina DS, Khaidukov SV, Nokel AY, Ryzhov IM, Henry SM, Bovin NV, Rapoport EM. 2024. International Journal of Molecular Sciences 25(11):5725. DOI: 10.3390/ijms25115725
  16. Effect of ligand and shell densities on the surface structure of core–shell nanoparticles self-assembled from function–spacer–lipid constructsVaskan I, Dimitreva V, Petoukhov M, Shtykova E, Bovin N, Tuzikov A, Tretyak M, Oleinikov V, Zalygin A. 2024. Biomaterials Science 12(3):798–806. DOI: 10.1039/D3BM01704D
  17. Galectin-9 as a Potential Modulator of Lymphocyte Adhesion to Endothelium via Binding to Blood Group H GlycanRapoport EM, Ryzhov IM, Slivka EV, Korchagina EY, Popova IS, Khaidukov SV, André S, Kaltner H, Gabius HJ, Henry S, Bovin NV. 2023. Biomolecules 13(8):1166. DOI: 10.3390/biom13081166
  18. Two point mutations in protocadherin-1 disrupt hantavirus recognition and afford protection against lethal infectionSlough MM, Li R, Herbert AS, Lasso G, Kuehne AI, Monticelli SR, Bakken RR, Liu Y, Ghosh A, Moreau AM, Zeng X, Rey FA, Guardado-Calvo P, Almo SC, Dye JM, Jangra RK, Wang Z, Chandran K. 2023. Nature Communications 14(1):4454. DOI: 10.1038/s41467-023-40126-y
  19. Henry SM, Flegel WA, Weinstock C. Continuous population surveillance of COVID-19 immunity can be provided by blood services at low cost using routine laboratory infrastructure. Blood Transfusion. 2022;20(6):525–526. DOI: 10.2450/2022.0150-22
  20. Rapid and specific detection of intact viral particles using functionalized microslit silicon membranes as a fouling-based sensorKlaczko ME, Lucas K, Salminen AT, McCloskey MC, Ozgurun B, Ward BM, Flax J, McGrath JL. 2022. The Analyst 147(2):213–222. DOI: 10.1039/D1AN01504D
  21. Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose ConjugationLiu Z, Li X, Lu Z, Qin X, Hong H, Zhou Z, Pieters RJ, Shi J, Wu Z. 2022. Journal of Pharmaceutical Sciences 111(10):2719–2729. DOI: 10.1016/j.xphs.2022.07.017
  22. Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantavirusesMittler E, Wec AZ, Tynell J, Guardado-Calvo P, Wigren-Byström J, Polanco LC, O’Brien CM, Slough MM, Abelson DM, Serris A, Sakharkar M, Pehau-Arnaudet G, Bakken RR, Geoghegan JC, Jangra RK, Keller M, Zeitlin L, Vapalahti O, Ulrich RG, Bornholdt ZA, Ahlm C, Rey FA, Dye JM, Bradfute SB, Strandin T, Herbert AS, Forsell MNE, Walker LM, Chandran K. 2022. Science Translational Medicine 14(636):eabl5399. DOI: 10.1126/scitranslmed.abl5399
  23. Simulated red blood cell antibody identification training panels created using SARS-CoV-2 kodecytes and immune plasmaPerry H, Henry SM. 2022. Transfusion 62(8):1630–1635. DOI: 10.1111/trf.17004
  24. Influence of the Lipid Moiety Structure on the Insertion/Release of Glycolipids in/from the Cell: A Study with Synthetic AnalogsSlivka EV, Tuzikov AB, Khaidukov SV, Komarova VA, Henry SM, Bovin NV, Rapoport EM. 2022. Russian Journal of Bioorganic Chemistry 48(5):932–936. DOI: 10.1134/S1068162022050235
  25. Erytra blood group analyser and kode technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individualsWeinstock C, Flegel WA, Srivastava K, Kaiser S, Schrezenmeier H, Tsamadou C, Ludwig C, Jahrsdörfer B, Bovin NV, Henry SM. 2022. eJHaem 3(1):72-79. DOI: 10.1002/jha2.352
  26. COVID-19 antibody screening with SARS-CoV-2 red cell kodecytes using routine serologic diagnostic platformsNagappan R, Flegel WA, Srivastava K, Williams EC, Ryzhov I, Tuzikov A, Galanina O, Shilova N, Sukhikh G, Perry H, Bovin NV, Henry SM. 2021. Transfusion 61(4):1171–1180. DOI: 10.1111/trf.16327
  27. Localization of synthetic glycolipids in the cell and the dynamics of their insertion/lossRapoport EM, Khasbiullina NR, Komarova VA, Ryzhov IM, Gorbatch MM, Tuzikov AB, Khaidukov SV, Popova IS, Korchagina EY, Henry SM, Bovin NV. 2021. Biochimica et Biophysica Acta (BBA) - Biomembranes 1863(9):183645. DOI: 10.1016/j.bbamem.2021.183645
  28. SARS-CoV-2 Peptide Bioconjugates Designed for Antibody DiagnosticsRyzhov IM, Tuzikov AB, Nizovtsev AV, Baidakova LK, Galanina OE, Shilova NV, Ziganshina MM, Dolgushina NV, Bayramova GR, Sukhikh GT, Williams EC, Nagappan R, Henry SM, Bovin NV. 2021. Bioconjugate Chemistry 32(8):1606-1616. DOI: 10.1021/acs.bioconjchem.1c00186
  29. COVID-19 Antibody Detection and Assay Performance Using Red Cell AgglutinationSrivastava K, West KA, De Giorgi V, Holbrook MR, Bovin NV, Henry SM, Flegel WA. 2021. Microbiology Spectrum 9(3). DOI: 10.1128/Spectrum.00830-21
  30. A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its InhibitionBortz RH, Wong AC, Grodus MG, Recht HS, Pulanco MC, Lasso G, Anthony SJ, Mittler E, Jangra RK, Chandran K. 2020. Journal of Virology 94(18):e00336-20. DOI: 10.1128/JVI.00336-20
  31. Incidence in plasma of low level antibodies against three xenotransplantation and immunotherapeutic glycan antigensPerry HE, Ryzhov I, Galanina O, Bovin NV, Henry SM. 2020. AIMS Allergy and Immunology 4(4):75–87. DOI: 10.3934/Allergy.2020007
  32. Kodecytes: modifying the surface of red blood cellsHenry S. 2020. ISBT Science Series 15(3):303–309. DOI: 10.1111/voxs.12545
  33. Structure of Supramers Formed by the Amphiphile Biotin‐CMG‐DOPEZalygin A, Solovyeva D, Vaskan I, Henry S, Schaefer M, Volynsky P, Tuzikov A, Korchagina E, Ryzhov I, Nizovtsev A, Mochalov K, Efremov R, Shtykova E, Oleinikov V, Bovin N. 2020. ChemistryOpen 9(6):641–648. DOI: 10.1002/open.201900276
  34. A standardized kodecyte method to quantify ABO antibodies in undiluted plasma of patients before ABO‐incompatible kidney transplantationPerry H, Bovin N, Henry S. 2019. Transfusion 59(6):2131–2140. DOI: 10.1111/trf.15247
  35. Synthesis of blood group Forssman pentasaccharide GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ–RPopova IS, Korchagina EY, Sablina MA, Paramonov AS, Hult AK, Henry SM, Bovin NV. 2019. Mendeleev Communications 29(5):578–580. DOI: 10.1016/j.mencom.2019.09.034
  36. Synthesis of glycans functioning as antigens of the ABO blood group systemRyzhov IM, Bovin NV. 2019. Mendeleev Communications 29(6):597–612. DOI: 10.1016/j.mencom.2019.11.001
  37. AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma modelsShaw SM, Middleton J, Wigglesworth K, Charlemagne A, Schulz O, Glossop MS, Whalen GF, Old R, Westby M, Pickford C, Tabakman R, Carmi-Levy I, Vainstein A, Sorani E, Zur AA, Kristian SA. 2019. Cancer Cell International 19:346. DOI: 10.1186/s12935-019-1059-8
  38. Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre VirusesWarner BM, Stein DR, Jangra RK, Slough MM, Sroga P, Sloan A, Frost KL, Booth S, Chandran K, Safronetz D. 2019. Viruses 11(7):645. DOI: 10.3390/v11070645
  39. Kode Technology: a universal cell surface glycan modification technologyHenry SM, Bovin NV. 2019. Journal of the Royal Society of New Zealand 49(2):100–113. DOI: 10.1080/03036758.2018.1546195
  40. Blood Group O→A Transformation by Chemical Ligation of ErythrocytesRyzhov IM, Tuzikov AB, Perry H, Korchagina EY, Bovin NV. 2019. ChemBioChem 20(2):131-133. DOI: 10.1002/cbic.201800289
  41. Real-time analysis of protein and protein mixture interaction with lipid bilayersHeider S, Reimhult E, Metzner C. 2018. Biochimica et Biophysica Acta (BBA) - Biomembranes 1860(2):319–328. DOI: 10.1016/j.bbamem.2017.10.024
  42. Applications for kodecytes in immunohaematologyHenry S, Perry H, Bovin N. 2018. ISBT Science Series 13(3):229–237. DOI: 10.1111/voxs.12403
  43. Rapid one-step biotinylation of biological and non-biological surfacesHenry S, Williams E, Barr K, Korchagina E, Tuzikov A, Ilyushina N, Abayzeed SA, Webb KF, Bovin N. 2018. Scientific Reports 8(1):2845. DOI: 10.1038/s41598-018-21186-3
  44. Protocadherin-1 is essential for cell entry by New World hantavirusesJangra RK, Herbert AS, Li R, Jae LT, Kleinfelter LM, Slough MM, Barker SL, Guardado-Calvo P, Román-Sosa G, Dieterle ME, Kuehne AI, Muena NA, Wirchnianski AS, Nyakatura EK, Fels JM, Ng M, Mittler E, Pan J, Bharrhan S, Wec AZ, Lai JR, Sidhu SS, Tischler ND, Rey FA, Moffat J, Brummelkamp TR, Wang Z, Dye JM, Chandran K. 2018. Nature 563(7732):559–563. DOI: 10.1038/s41586-018-0702-1
  45. Visualizing Oncolytic Virus-Host Interactions in Live Mice Using Intravital MicroscopyNaumenko V, Van S, Dastidar H, Kim DS, Kim SJ, Zeng Z, Deniset J, Lau A, Zhang C, Macia N, Heyne B, Jenne CN, Mahoney DJ. 2018. Molecular Therapy - Oncolytics 10:14–27. DOI: 10.1016/j.omto.2018.06.001
  46. Tailor-made Janus lectin with dual avidity assembles glycoconjugate multilayers and crosslinks protocellsRibeiro JP, Villringer S, Goyard D, Coche-Guerente L, Höferlin M, Renaudet O, Römer W, Imberty A. 2018. Chemical Science 9(39):7634–7641. DOI: 10.1039/c8sc02730g
  47. Evaluation of kodecytes using function‐spacer‐lipid constructs as a survey material for external proficiency testing for ABO subgroupingLim YA, Kang SJ. 2017. Journal of Clinical Laboratory Analysis 31(6):e22116. DOI: 10.1002/jcla.22116
  48. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against EbolavirusesWec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega MA, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA. 2017. Cell 169(5):878-890.e15. DOI: 10.1016/j.cell.2017.04.037
  49. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of VulnerabilityZhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ. 2017. Cell 169(5):891-904.e15. DOI: 10.1016/j.cell.2017.04.038
  50. Biofunctionalizing nanofibers with carbohydrate blood group antigensBarr K, Kannan B, Korchagina E, Popova I, Ryzhov I, Henry S, Bovin N. 2016. Biopolymers 105(11):787–794. DOI: 10.1002/bip.22907
  51. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding SiteHowell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ. 2016. Cell Reports 15(7):1514–1526. DOI: 10.1016/j.celrep.2016.04.026
  52. Incorporation of fluorescein conjugated function-spacer-lipid constructs into the red blood cell membrane facilitates detection of labelled cells for the duration of ex vivo storageKi KK, Flower RL, Faddy HM, Dean MM. 2016. Journal of Immunological Methods 429:66–70. DOI: 10.1016/j.jim.2016.01.003
  53. Antibody complement-mediated hemolytic studies with kodecytes reveal that human complement utilized in the classical pathway is more stable than generally acceptedPerry H, Bovin N, Henry S. 2016. Transfusion 56(10):2495–2501. DOI: 10.1111/trf.13719
  54. Function-spacer-lipid constructs of Lewis and chimeric Lewis/ABH glycans. Synthesis and use in serological studiesRyzhov IM, Korchagina EY, Tuzikov AB, Popova IS, Tyrtysh TV, Pazynina GV, Henry SM, Bovin NV. 2016. Carbohydrate Research 435:83-96. DOI: 10.1016/j.carres.2016.09.016
  55. Ultra-fast glyco-coating of non-biological surfacesWilliams E, Barr K, Korchagina E, Tuzikov A, Henry S, Bovin N. 2016. International Journal of Molecular Sciences 17(1):118. DOI: 10.3390/ijms17010118
  56. Glycomapping the fine specificity of monoclonal and polyclonal Lewis antibodies with type‐specific Lewis kodecytes and function‐spacer‐lipid constructs printed on paperWilliams E, Korchagina E, Frame T, Ryzhov I, Bovin N, Henry S. 2016. Transfusion 56(2):325–333. DOI: 10.1111/trf.13384
  57. Monoclonal anti‐A activity against the FORS1 (Forssman) antigenBarr K, Korchagina E, Popova I, Bovin N, Henry S. 2015. Transfusion 55(1):129–136. DOI: 10.1111/trf.12773
  58. Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane FusionKleinfelter LM, Jangra RK, Jae LT, Herbert AS, Mittler E, Stiles KM, Wirchnianski AS, Kielian M, Brummelkamp TR, Dye JM, Chandran K. 2015. mBio 6(4):e00801-15. DOI: 10.1128/mBio.00801-15
  59. Synthetic glycolipid-like constructs as tools for glycobiology research, diagnostics, and as potential therapeuticsKorchagina EY, Henry SM. 2015. Biochemistry (Moscow) 80(7):857–871. DOI: 10.1134/S0006297915070068
  60. Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in batsNg M, Ndungo E, Kaczmarek ME, Herbert AS, Binger T, Kuehne AI, Jangra RK, Hawkins JA, Gifford RJ, Biswas R, Demogines A, James RM, Yu M, Brummelkamp TR, Drosten C, Wang LF, Kuhn JH, Müller MA, Dye JM, Sawyer SL, Chandran K. 2015. eLife 4:e11785. DOI: 10.7554/eLife.11785
  61. Training students in serologic reaction grading increased perceptions of self-efficacy and ability to recognise serologic reactions but decreased grading accuracyPerry H, Henry S. 2015. Transfusion 55(6pt2):1572–1579. DOI: 10.1111/trf.12985
  62. Mapping the fine specificity of ABO monoclonal reagents with A and B type-specific function-spacer-lipid constructs in kodecytes and inkjet printed on paperBarr K, Korchagina E, Ryzhov I, Bovin N, Henry S. 2014. Transfusion 54(10):2477–2484. DOI: 10.1111/trf.12661
  63. Labeling of influenza viruses with synthetic fluorescent and biotin-labeled lipidsIlyushina NA, Chernyy ES, Korchagina EY, Gambaryan AS, Henry SM, Bovin NV. 2014. Virologica Sinica 29(4):199-210. DOI: 10.1007/s12250-014-3475-1
  64. Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann–Pick C1Ng M, Ndungo E, Jangra RK, Cai Y, Postnikova E, Radoshitzky SR, Dye JM, Ramírez de Arellano E, Negredo A, Palacios G, Kuhn JH, Chandran K. 2014. Virology 468-470:637–646. DOI: 10.1016/j.virol.2014.08.019
  65. PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized MiceTesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ. 2013. Journal of Virology 87(7):3752–3759. DOI: 10.1128/JVI.02832-12
  66. An improved Fc function assay utilizing CMV antigen-coated red blood cells generated with synthetic function–spacer–lipid constructsGeorgakopoulos T, Komarraju S, Henry S, Bertolini J. 2012. Vox Sanguinis 102(1):72–78. DOI: 10.1111/j.1423-0410.2011.01512.x
  67. Modeling transfusion reactions with kodecytes and enabling ABO-incompatible transfusion with function-spacer-lipid constructsHenry SM, Barr KL, Oliver CA. 2012. ISBT Science Series 7(1):106–111. DOI: 10.1111/j.1751-2824.2012.01563.x
  68. Flow cytometry evaluation of red blood cells mimicking naturally occurring ABO subgroups after modification with variable amounts of function-spacer-lipid A and B constructsHult AK, Frame T, Chesla S, Henry S, Olsson ML. 2012. Transfusion 52(2):247–251. DOI: 10.1111/j.1537-2995.2011.03268.x
  69. Toward creating cell membrane glyco-landscapes with glycan lipid constructsKorchagina E, Tuzikov A, Formanovsky A, Popova I, Henry S, Bovin N. 2012. Carbohydrate Research 356:238–246. DOI: 10.1016/j.carres.2012.03.044
  70. Fluorescent Function-Spacer-Lipid construct labelling allows for real-time in vivo imaging of cell migration and behaviour in zebrafish (Danio rerio)Lan CC, Blake D, Henry S, Love DR. 2012. Journal of Fluorescence 22(4):1055–1063. DOI: 10.1007/s10895-012-1043-3
  71. Prevalence and specificity of red blood cell antibodies in a multiethnic South and East Asian patient population, and the influence of using novel MUT+Mur+ kodecytes on its detectionNadarajan VS, Laing AA, Saad SM, Usin M. 2012. Vox Sanguinis 102(1):65–71. DOI: 10.1111/j.1423-0410.2011.01507.x
  72. FSL constructs: a simple method for modifying cell and virion surfaces with a range of biological markers without affecting their viabilityBlake DA, Bovin NV, Bess D, Henry SM. 2011. Journal of Visualized Experiments (54):e3289. DOI: 10.3791/3289
  73. Fluorescein and radiolabeled Function-Spacer-Lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virionsHadac EM, Federspiel MJ, Chernyy E, Tuzikov A, Korchagina E, Bovin NV, Russell SJ, Henry SM. 2011. Journal of Virological Methods 176(1–2):78–84. DOI: 10.1016/j.jviromet.2011.06.005
  74. A Novel VSV/HIV Pseudotype Approach for the Study of HIV Microbicides Without Requirement for level 3 BiocontainmentHarrison AL, Henry S, Mahfoud R, Manis A, Albertini A, Gaudin Y, Lingwood CA, Branch DR. 2011. Future Virology 6(10):1241–1259. DOI: 10.2217/fvl.11.88
  75. Designing peptide-based FSL constructs to create Miltenberger kodecytesHenry SM, Komarraju S, Heathcote D, Rodionov IL. 2011. ISBT Science Series 6(2):306–312. DOI: 10.1111/j.1751-2824.2011.01505.x
  76. In vivo neutralization of anti-A and successful transfusion of A antigen–incompatible red blood cells in an animal modelOliver C, Blake D, Henry S. 2011. Transfusion 51(12):2664–2675. DOI: 10.1111/j.1537-2995.2011.03184.x
  77. Modeling transfusion reactions and predicting in vivo cell survival with kodecytesOliver C, Blake D, Henry S. 2011. Transfusion 51(8):1723–1730. DOI: 10.1111/j.1537-2995.2010.03034.x
  78. A synthetic globotriaosylceramide analogue inhibits HIV-1 infection in vitro by two mechanismsHarrison AL, Olsson ML, Jones RB, Ramkumar S, Sakac D, Binnington B, Henry S, Lingwood CA, Branch DR. 2010. Glycoconjugate Journal 27(5):515–524. DOI: 10.1007/s10719-010-9297-y
  79. Novel antibody screening cells, MUT+Mur kodecytes, created by attaching peptides onto red blood cellsHeathcote D, Carroll T, Wang JJ, Flower R, Rodionov I, Tuzikov A, Bovin N, Henry S. 2010. Transfusion 50(3):635–641. DOI: 10.1111/j.1537-2995.2009.02480.x
  80. Modification of red blood cells for laboratory quality control useHenry SM. 2009. Current Opinion in Hematology 16(6):467–472. DOI: 10.1097/MOH.0b013e328331257e
  81. Synthetic glycolipid modification of red blood cell membranesFrame T, Carroll T, Korchagina E, Bovin N, Henry S. 2007. Transfusion 47(5):876–882. DOI: 10.1111/j.1537-2995.2007.01204.x

Papers on related biology, comparator methods and reviews, listed for context. They are not presented as Kode Technology studies.

Conference abstracts and proceedings (69)

  1. Ellis S, Henry S. Kv9 a novel cancer immunotherapeutic for solid tumours in dogs. New Zealand Veterinary Association Conference, Wellington, 2025.
  2. Henry S, Obukhova P, Tuzikov A, Ryzhov I, Tsygankova S, Bovin N. Identification of the common epitope present on both A and B antigens recognized by anti-A,B but not by anti-A or anti-B. 5th Australasian Glycoscience Symposium 2024.
  3. Datta SS, Henry SM. A novel syphilis treponemal TmpA peptide antigen diagnostic assay using red cell kodecytes in routine immunohematology column agglutination testing platforms. ISBT Barcelona 2024.
  4. Weinstock C, Flegel WA, Srivastava K, Bovin NV, Henry SM, Kaiser S, Schrezenmeier H, Tsamadou C, Jahrsdörfer B. Usability of the ERYTRA Blood Group Analyser for Testing for Antibodies against SARS-CoV-2. German Society of Transfusion Medicine and Immunohaematology (DGTI) 2021.
  5. Maslennikov AM, Zalygin AV, Shtykova EV, Bovin NV, Oleinikov VA. Small-angle X-ray (SAXS) and Raman spectroscopy studies of biot-CMG(2)-DOPE quasicrystalline phases. Journal of Physics: Conference Series. 2021;2058(1):012018. DOI: 10.1088/1742-6596/2058/1/012018
  6. Tarasova AR, Vaskan IS, Zalygin AV, Troitskaya PS, Bovin NV, Oleinikov VA. Loading efficiency of doxorubicin into the micelle-like structures formed by function-spacer-lipid constructs self-assembly depends on constructs’ functional part. Journal of Physics: Conference Series. 2021;2058(1):012003. DOI: 10.1088/1742-6596/2058/1/012003
  7. Henry S. Kodecytes: modifying the surface of red cells (plenary invited). Regional congress of the International Society of Blood Transfusion (ISBT), Bangkok, Thailand, November 16-19, 2019.
  8. Henry S. ASK – advanced serological kodecytes specifically designed for teaching. Invitational Congress of Investigational Immunohematologists (ICII), Toledo, USA, June 2019.
  9. Henry S. Quantitating ABO antibodies in undiluted plasma with kodecytes. Invitational Congress of Investigational Immunohematologists (ICII), Toledo, USA, June 2019.
  10. Henry S, Perry H, Bovin N. Applications for kodecytes in immunohematology. (plenary invited) 28th Regional Congress of the ISBT, Guangzhou, China, November 2017.
  11. Croft SA, Seale RB, Bovin N, Henry S. Novel anti-microbial construct coatings that can prevent bacterial biofilm development on metal and other surfaces. NZ Microbiology Society Annual Conference, Christchurch, November 2016.
  12. Perry H, Henry SM. Standardized blood group A kodecytes allow for determination of anti-A,B titres without the need for sample dilution (SP248). AABB Florida, October 2016, Transfusion 2016; S4, 3A-262. DOI: 10.1111/trf.13807
  13. Perry H, Henry SM. Controlling antigen-antibody mediated hemolysis by manipulating the amount of antigen on the RBC surface on heterophile kodecytes. AABB Florida, October 2016 (SP252). AABB Florida, October 2016, Transfusion 2016; S4, 3A-262. DOI: 10.1111/trf.13807
  14. Henry S. FSL constructs: a novel suite of tools for the attachment of virtually anything onto any surface. Merck Millipore – The use of microspheres and nanospheres in diagnostics and life sciences (invited) Shanghai, China May 2014.
  15. Henry S. FSL immobilization of red cells on solid surfaces. Invitational Congress of Investigational Immunohematologists (ICII), Minneapolis, USA, June 2013.
  16. Henry S. Evidence that ABO reagents can detect the wrong ABO or non-ABO antigens. Invitational Congress of Investigational Immunohematologists (ICII), Minneapolis, USA, June 2013.
  17. Henry S. Teaching serology by controlling IgM/IgG sensitization and antibody mediated hemolysis with kodecytes. Invitational Congress of Investigational Immunohematologists (ICII), Minneapolis, USA, June 2013.
  18. Perry EH, Henry SM. Teaching the recognition of hemolysis by controlling antibody mediated in vitro hemolysis with kodecytes. AABB, Denver 2013 Transfusion 2013; 53 (Suppl.), 182A.
  19. Henry S. KODE cell surface modification allows for the creation of basic and advanced serologic training tools. (invited) NZIMLS, Hamilton 2013.
  20. Korchagina E, Tuzikov A, Rodionov I, Stowell S, Perry H, Bovin N, Henry S. Cell landscape engineering. FEBS 38th Congress, St Petersburg, Russia July 2013 FEBS J 2013; 280 (Suppl.1), 527-528 (SW06.S28-8).
  21. Henry S, Korchagina E, Tuzikov A, Bovin N. Glycoengineering the surface of living cells. Joint Meeting of The American Society for Matrix Biology and the Society for Glycobiology. San Diego, California, USA 2012.
  22. Henry S, Korchagina E, Tuzikov A, Bovin N. Glycolandscaping living cells. 26th International Carbohydrate Symposium, Madrid Spain 2012.
  23. Perry EH, Henry SM. Measuring serologic reaction grading skill with kodecytes at an accredited teaching institution. AABB Boston, 2012 Transfusion 2012; 52 (Suppl.1), 234A.
  24. Henry S. Transfusion medicine & KODE Technology: R&D tools, QC systems, diagnostics & therapeutics. British Blood Transfusion Society Red Cell Special Interest Group, (invited) Harrogate, UK 2012.
  25. Perry H & Henry S. Improving skill in serologic reaction grading with A+B kodecytes. ISBT Cancun, Mexico 2012 Vox Sanguinis 2012; 103 (s1), 192-193.
  26. Henry S. Modeling transfusion reactions with kodecytes and enabling ABO-incompatible transfusion with Function-Spacer-Lipid constructs. (invited) ISBT Cancun, Mexico 2012 Vox Sanguinis 2012; 103 (s1), 14.
  27. Henry S. KODE Technology biosurface engineering. Medical Technology Association of NZ, Auckland, 2012 New Zealand.
  28. Tesfay MZ, Krik AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Russell SJ. PEGylation of Vesicular Stomatitis Virus (VSV) extends virus persistence in blood in the presence of neutralizing antibodies. American Society of Gene & Cell Therapy 15th Annual Meeting, Philadelphia 2012 Molecular Therapy 2012; 20 (suppl 1) S85.
  29. Flower RL, Heathcote D, Lin P-H, Henry S, Lin M. Comparison of kodecytes serology, peptide ELISA and peptide affinity chromatography for characterisation of antibodies to MNS system hybrid glycophorin antigens. 22nd Regional Congress of the ISBT, November 2011, Taipei, Taiwan. Vox Sanguinis 2011; 101 (Suppl. 2): 16.
  30. Henry S, Korchagina E, Tuzikov A, Formanovsky A, Popova I, Bovin N. Towards cell glycolandscape. XXI International Symposium on Glycoconjugates, Vienna, Austria 2011 Glycoconjugate J 2011; 28: 258.
  31. Flower R, Heathcote D, Henry S: Insertion of Kode™ peptide constructs into red cell membranes: Artificial blood group antigens found on MNS hybrid glycophorins. 37th Annual Conference of Indian Society of Blood Transfusion and Immunohematology (ISBTI). Asian J Transfusion Science 2011;5:63-109 http://www.ajts.org/text.asp?2011/5/1/63/76033.
  32. Henry S, Komarraju S, Heathcote D, Rodinov I. Kodecytes and Miltenberger (invited). 22nd Regional Congress of the ISBT, November 2011, Taipei, Taiwan. Vox Sanguinis 2011; 101 (Suppl. 2): 5.
  33. Barr K, Diegel O, Parker S, Henry S. A novel solution for diagnostic printing. NZBio Conference 2011, Auckland, New Zealand.
  34. Barr K, Diegel O, Parker S, Henry S. Inkjet printing of Function-Spacer-Lipid (FSL) biomolecules. NZ Rapid Product Development Conference 2011, Auckland, New Zealand.
  35. Henry S, Korchagina E, Tuzikov A, Bovin NV. Glyco-landscaping with neo glycolipid constructs. Glycobiology 2010, Florida Glycobiology 2010; 20 (11): 1472.
  36. Chesla S, Henry S, Eatz R, Sinor L. Solid phase syphilis test utilizing KODE™ technology. AABB 2010 Annual Meeting, October 2010, Baltimore, Maryland, USA Transfusion 50 (Suppl. 1 ):196A-197A; 2010. DOI: 10.1111/j.1537-2995.2010.02833_1.x
  37. Oliver C, Blake D, Ferguson S, Bovin N, Henry S. Biotin-kodecytes - novel function-spacer-lipid (FSL) modified cells capable of being recovered from the circulation after 3 days. 35th FEBS Congress, June 2010, Sweden. FEBS Journal 277 (Suppl. 1):50-51;2010.
  38. Komarraju S, Chesla S, Bovin N, Henry S. Syphilis-kodecytes - novel function-spacer-lipid (FSL) modified red cells capable of sensitive and specific detection of syphilis antibodies. 35th FEBS Congress, June 2010, Sweden. FEBS Journal 277 (Suppl. 1):97-98;2010.
  39. Barr K, Diegel O, Parker S, Bovin N, Henry S. Function-Spacer-Lipid (FSL) constructs enable inkjet printing of blood group antigens. 35th FEBS Congress, June 2010, Sweden. FEBS Journal 277 (Suppl. 1):235;2010.
  40. Blake D, Lan A, Love D, Bovin N, Henry S. Fluorophore-kodecytes - fluorescent function-spacer-lipid (FSL) modified cells for in vitro and in vivo analyses. 35th FEBS Congress, June 2010, Sweden. FEBS Journal 277 (Suppl. 1):199;2010.
  41. Harrison, A.L., Kim, M., McCarthy, S.D.S., Henry, S., Lingwood, C.A, and Branch, D.R.: Synthetic Pk inhibits HIV-1 infection in vitro by two mechanisms. 19th Annual Canadian Conference of HIV/AIDS Research, Saskatoon, SK, May 2010. Can J Infec Dis Med Microbiol 21(Suppl B):25B, 2010.
  42. Harrison, A.L., McCarthy, S.D.S., Kim, M., Henry, S., Lingwood, C., and Branch, D.R.: Soluble globotriaosylceramide as a potential microbicide for the prevention of HIV-1 infection. 19th Annual Canadian Conference of HIV/AIDS Research, Saskatoon, SK, May 2010 Can J Infec Dis Med Microbiol 21(Suppl B):26B, 2010.
  43. Henry S. CSL & KODE Biotech = 6 offspring (and still pregnant). NZBio Conference. (Invited). Auckland (March 2010).
  44. Henry S. Kodecytes – designer red cells created with KODE™ biosurface engineering technology ANZ Society of Blood Transfusion. (Invited plenary). Adelaide, Australia (October 2009) Transfusion Medicine 2010; 20:204. DOI: 10.1111/j.1365-3148.2010.01002.x
  45. Henry S. KODE technology – changing the face of serology. (Keynote speaker). Invitational Congress of Investigational Immunohematologists (ICII). Asilomar, USA June 2009.
  46. Heathcote D, Flower R, Henry S. Development and validation of antibody screening cells specifically designed for Asian populations – the first example of the addition of peptide antigens to human red cells using KODE™ technology. The Annual Scientific Meeting of the Australian and New Zealand Society of Blood Transfusion, October 2008, Perth, Australia.
  47. El-Aklouk E, Al-Jumaily AM, White D, Henry S. Feasibility of delivering a novel synthetic membrane anchor to the deep lungs. ASME International Mechanical Engineering Congress & Exposition. October 2008, Boston, USA.
  48. Henry S. Creating designer cells with synthetic peptidolipids, glycolipids and other lipid linked nanostructures. Micro/Nano Technology Society-wide Forum. ASME International Mechanical Engineering Congress & Exposition. October 2008, Boston, USA.
  49. Henry S. KODE™ technology: A novel in vitro and in vivo cell surface modification technology (invited plenary). ASME International Mechanical Engineering Congress & Exposition. October 2008, Boston, USA.
  50. Branch DR, Harrison A, Sakac D, Lingwood C, Henry S. A synthetic, water dispersible glycolipid analogue of the Pk blood group antigen completely blocks HIV-1 infection. AABB 2008 Annual Meeting, October 2008, Montréal, Québec, Canada. Transfusion 2008; 48 (2S) Suppl.: 104A. DOI: 10.1111/j.1537-2995.2008.01891.x
  51. Henry S, Bovin N. The development of synthetic peptidolipids, glycolipids and other lipid-linked structures to create designer red cells. AABB 2008 Annual Meeting, October 2008, Montréal, Québec, Canada Transfusion 2008; 48 (2S) Suppl.: 203A. DOI: 10.1111/j.1537-2995.2008.01891.x
  52. Hult AK, Frame T, Henry S, Olsson ML. Flow cytometry evaluation of red blood cells transformed with variable amounts of synthetic A and B glycolipids. ISBT Regional Congress, Macao SAR China, 2008. (P-322) Vox Sanguinis 2008; 95 (S1), 180.
  53. Heathcote D, Flower R, Henry S. Development and validation of antibody screening cells specifically designed for Asian populations – the first example of the addition of peptide antigens to human red cells using KODE™ technology. ISBT Regional Congress, Macao SAR China, 2008. Vox Sanguinis 2008; 95(S1):174.
  54. Flower R, Lin P-H, Heathcote D, Chan M, Teo D, Selkirk A, Shepherd R, Henry S. Insertion of KODE™ peptide constructs into red cell membranes: Creating artificial variant MNS blood group antigens. ISBT Regional Congress, Macao SAR China, 2008. (P-396) Vox Sanguinis 2008; 95(S1), 203-204.
  55. Henry S, Flower R. A potential new technique to study epitope specificity of antibodies to variant MNS blood group antigens. Australian and New Zealand Society of Blood Transfusion, Gold Coast, October, Australia, 2007.
  56. Henry S. Water soluble synthetic glycolipids. Society for Glycobiology Meeting, Boston, USA, 2007 Glycobiology 2007; 17: 1267.
  57. Henry S. KODE™ technology: A new in vitro and in vivo technological platform (invited speaker). South Pacific Congress, Auckland, 2007.
  58. Harrison AL, Yuan R, Manis A, Mylvaganam M, Henry S, Lingwood C, Branch DR. Establishment of a level 2 mouse model for the study of microbicide prevention of vaginal and rectal HIV transmission 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007.
  59. Blake D, Carter N, Erikson E, Williams E, Henry S. Embryo cell surface and zona modification via a novel KODE™ Technology. 19th World Congress on Fertility and Sterility: International Federation of Fertility Societies, Durban, South Africa 2007.
  60. Blake D, Carter N, Erikson E, McIntosh S, Stockman C, Weinberg C, Williams E, Henry S. KODE™ Alteration of Cell Surface Characteristics. NZBio Conference, Auckland, NZ, 2007 (poster).
  61. Henry S. Cell antigen paint (KODE™ technology): A new in vitro and in vivo immunological platform technology. Plenary Lecture. Australasian Society of Immunology, Auckland, 2006.
  62. Frame T, Henry S, Mobley D, Chesla S. Attachment of synthetic carbohydrate antigens to red blood cells using KODE™ technology. AABB Meeting 2006, Miama, USA, 2006 Transfusion 2006; 46 (suppl. 9S): 32A.
  63. Henry SM, Carroll T, Frame T. KODE™ technology allows the attachment of carbohydrate blood group antigens to red cells. XXIXth Congress of the International Society of Blood Transfusion, Cape Town, South Africa, 2006 Vox Sangunis 2006; 91 (suppl.3): 29.
  64. Henry SM. Modifying red cells with synthetic glycolipids bearing carbohydrate blood group glycotopes. XXIIIrd International Carbohydrate Symposium Organizers, Whistler, Canada, 2006.
  65. Henry SM. KODE™ CAE: creating the world’s first ABO analytical control system. (invited lecture) Annual Scientific Meeting, Australian and New Zealand Society of Blood Transfusion, Sydney, Australia, 2005 Transfusion Medicine 2006; 16: 217.
  66. Henry SM. Engineering the surface of red cells with synthetic glycolipids (KODETM CAE) to create ABO analytical sensitivity controls and xeno-modified cells. (invited lecture) 2nd International Symposium on ABO Incompatibility in Transplantation, Göteborg, Sweden, 2005 Xenotransplantation 2005; 12(5): 356.
  67. Gilliver LG, Henry SM. World’s first blood grouping sensitivity control: created with KODE™ CAE technology. NZ Bio Conference, Auckland, 2005.
  68. Henry SM. Synthetic ABO molecules inserted into group O cells for use as ABO quality control cells. (Invited lecture) NZIMLS Conference, Hamilton, NZ, 2004.
  69. Henry SM, Gilliver L, McDonald R, Allan J. Glycoconjugate engineering of red cell surfaces (KODE-CAE) to create ABO phenotyping sensitivity controls. ISBT VIII European Congress, Istanbul, Turkey 2003.

Work with us: custom constructs and licensing

Commission a custom FSL construct, license Kode Technology for a new application, or extend your research with R&D constructs from our catalogue.